You can buy this undiscovered Goldmine currently at almost all time low .GLTA
FDA approval for the "Best in Class topical medication" on March 4 ,2013 . Nuvo has already a great Partnership with Big Player Covidien in place .
Nuvo will hit profitability this year with 2 new product launches in 2Q 2013 .
Upcoming Milestones 2013 :
March 4, 2013 PDUFA date for Pennsaid 2%
Q2 2013 worldwide launch of Pliaglis by Galderma
Nuvo Research (NRI.TO) or (NRIFF)
Market Cap : $ 36 M
Cash: $ 12 M
Price 0.065 $
Growing revenue with 3 approved pain products:
Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
U.S., targeting $8B oral NSAID market
Pliaglis®: analgesic peelable cream, targeting global cosmetic and
dermatology markets, partnered with Galderma, worldwide launch
commencing Q2 2013